Dynavax Technologies Co. (NASDAQ:DVAX) was the recipient of unusually large options trading on Monday. Investors bought 2,440 put options on the stock. This is an increase of approximately 1,352% compared to the average volume of 168 put options.
In related news, insider Robert Coffman sold 7,500 shares of the business’s stock in a transaction that occurred on Wednesday, December 13th. The stock was sold at an average price of $18.90, for a total transaction of $141,750.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP David Louis Johnson sold 3,092 shares of the business’s stock in a transaction that occurred on Thursday, January 4th. The stock was sold at an average price of $18.60, for a total value of $57,511.20. Following the sale, the vice president now directly owns 7,780 shares in the company, valued at approximately $144,708. The disclosure for this sale can be found here. 2.90% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Dynavax Technologies by 474.2% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,120 shares of the biopharmaceutical company’s stock valued at $153,000 after buying an additional 5,880 shares during the period. Cubist Systematic Strategies LLC boosted its stake in shares of Dynavax Technologies by 54.5% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 10,493 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 3,700 shares during the period. Legal & General Group Plc boosted its stake in shares of Dynavax Technologies by 18.5% during the 2nd quarter. Legal & General Group Plc now owns 12,501 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 1,950 shares during the period. Wall Street Access Asset Management LLC acquired a new stake in shares of Dynavax Technologies during the 2nd quarter valued at $124,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Dynavax Technologies during the 3rd quarter valued at $287,000. Hedge funds and other institutional investors own 70.54% of the company’s stock.
Dynavax Technologies (DVAX) opened at $16.85 on Thursday. Dynavax Technologies has a 52-week low of $3.70 and a 52-week high of $24.45. The firm has a market cap of $1,020.00, a P/E ratio of -8.60 and a beta of 1.31.
Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings data on Friday, November 3rd. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.15. Dynavax Technologies had a negative net margin of 1,177.60% and a negative return on equity of 65.97%. The firm had revenue of $0.05 million for the quarter, compared to analysts’ expectations of $0.28 million. During the same period in the previous year, the company posted ($0.90) EPS. The company’s quarterly revenue was down 68.8% compared to the same quarter last year. sell-side analysts expect that Dynavax Technologies will post -1.72 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Traders Buy High Volume of Put Options on Dynavax Technologies (DVAX)” was published by Markets Daily and is the sole property of of Markets Daily. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.themarketsdaily.com/2018/01/11/traders-buy-high-volume-of-put-options-on-dynavax-technologies-dvax.html.
Dynavax Technologies Company Profile
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.